Wolfe Research upgrades Moderna to Peer Perform on cancer therapy prospects
Wolfe Research upgraded Moderna (MRNA) to Peer Perform from Underperform, citing a clearer path to approval for its cancer therapy developed with Merck and projecting $9.2 billion in peak sales across four cancer indications following a Phase 3 win.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@schaeffers
Moderna $MRNA extends its comeback as Wolfe Research upgrades the stock to Peer Perform from Underperform. The firm now sees a clearer path to approval for its cancer therapy with Merck $MRK and projects $9.2 BILLION in peak sales across 4 cancer indications.
@MSBIntel
Wolfe Research upgrades Moderna on positive cancer-therapy trial data for intismeran.
@schaeffers
Moderna $MRNA's massive move is starting to change the Wall Street narrative. Wolfe upgraded shares after the Phase 3 win, sees limited downside into October's full data release and estimates $9.2B in peak sales potential across 4 cancer indications.